Skip to content
Search

Latest Stories

Community pharmacies in NI witnesses highest level of dispensing record in 2022/23

Community pharmacies were responsible for dispensing over 99 per cent of items in 2022/23, revealed General Pharmaceutical Services for Northern Ireland, Annual Statistics 2022/23 published on Thursday (29 June).

While the remaining one per cent dispensed by appliance contractors and dispensing doctors.


According to the statistics, on average, each community pharmacy dispensed over 84,000 items in 2022/23, witnessing a growth of over 3 per cent on the previous year to 44.6 million in 2022/23, which is the highest level of dispensing recorded.

This equated to BSO processing 2.1 million prescription forms per month, on average, throughout the year, representing a 4 per cent increase on the just over 2.0m processed each month last year.

The total ingredient cost over the year was £486.9 million. This was an increase of approaching 7 per cent on the previous year, which was around double the percentage increase in the number of items dispensed. The annual ingredient cost total has fluctuated since the beginning of the series but was over 18 per cent higher in 2022/23 than in 2013/14.

Approximately one-quarter (25%) of all items dispensed in 2022/23 were categorised as mainly treating conditions of the Central Nervous System. These items accounted for over one fifth (21%) of total ingredient cost.

Around 45 per cent of prescription items for which the age of the patient could be determined were dispensed to patients aged 65 or over, with over one-third (34%) dispensed to patients in the 45 to 64 age group.

The number of items dispensed in the most deprived areas in Northern Ireland was 46 per cent higher than in the least deprived. Conversely, the average ingredient cost per item was over 20 per cent higher in the least deprived areas.

One in four females (25%) in Northern Ireland received anti-depressant medication during 2022/23. The equivalent figure for males was 15 per cent. The proportion of the population receiving anti-depressant medication was over one and a half times higher in most deprived areas compared with the most affluent.

Northern Ireland had the highest ingredient cost per person in the UK in the 2022 calendar year, at just over £245. This was almost 40 per cent  higher than England, where the ingredient cost per person was just over £176 in 2022.

The report also revealed that by the end of 2022/23, Northern Ireland had 525 community pharmacies, one fewer than last year.

It also highlighted that people in Northern Ireland live, on average, less than one mile from a community pharmacy. However, there is a distinct variation in urban and rural settings, with Belfast Local Government District residents living, on average, 0.3 miles from their nearest pharmacy, compared with 1.6 miles for those living in Fermanagh and Omagh.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less